Roche has secured US Food and Drug Administration (FDA) 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test to detect a suspected heart attack.
The tropopin testing will help in the diagnosis of myocardial infarction and aid in accurate identification of patients experiencing heart attack.
Go deeper with GlobalData
The Elecsys Troponin T Gen 5 STAT test detects cardiac troponin which is released into the blood stream after the cardiac cells are damaged.
Troponin is considered as the biomarker for the diagnosis of heart attack and is marked as the gold standard in combination with an electrocardiogram (ECG) and signs of ischemia.
The test operates with higher sensitivity and takes time of about nine minutes which enables faster decision-making, while enabling detection of smaller infarctions and facilitate an effective treatment.
Baylor Medical Center Houston physician Frank Peacock said: "As an emergency doctor whose job is to make decisions on patients with chest pain, my ability to do this safely and accurately is driven by the sensitivity of the troponin assay.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“FDA clearance of this new Roche TnT assay is easily the best news in the last decade for emergency medicine patients presenting with chest pain."
The TnT diagnostic tests have demonstrated their clinical disgnostic functionality and have been available since the past seven years across the world.
